ArticleJournal of clinical microbiology2012
Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains.
Article in Journal of clinical microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation of the health and healthcare system burden due to antimicrobial-resistant Escherichia coli infections in humans: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2020Pooled it
- Rapid phenotypic antimicrobial susceptibility testing of Gram-negative bloodstream isolates: clinical evaluation of the LifeScale AST system.BMC microbiology · 2026Article
- Meningoencephalitis Caused by Escherichia coli in an Adult With No Known Immunocompromising Conditions: A Case Report.The American journal of case reports · 2026Article
- Third generation cephalosporin-resistant (3GCR) Escherichia coli and biocide-tolerant heterotrophic bacteria in irrigation water used in Capsicum annuum cultivation areas in Kosovo.Scientific reports · 2026Article
- Genetic Basis of Multiple Antibiotic Resistance of PathogenicInternational journal of molecular sciences · 2025Article
- Clinical and Demographic Features Associated with the Isolation of Ceftriaxone-Resistant Enterobacteriaceae in a Private Hospital in Kingston, Jamaica.The American journal of tropical medicine and hygiene · 2025Article
- Unveiling the impact: COVID-19's influence on bacterial resistance in the Kingdom of Bahrain.World journal of virology · 2025Article
- Risk factors associated with multidrug-resistant Klebsiella pneumoniae infections: a multicenter observational study in Lebanese hospitals.BMC public health · 2024Observational
- Appropriateness of Empiric Initiation of Meropenem in the Intensive Care Unit as Determined by Internal Medicine Residents.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Extended-Spectrum β-Lactamases (ESBL): Challenges and Opportunities.Biomedicines · 2023Review
- Empiric antimicrobial therapy in the intensive care unit based on the risk of multidrug-resistant bacterial infection: a single-centre case‒control study of blood culture results in Japan.Antimicrobial resistance and infection control · 2023Article
- Factors Associated with Extended-spectrum β-lactamase-producing Enterobacteria Isolated from Respiratory Samples.Internal medicine (Tokyo, Japan) · 2023Article
- The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020).Journal of intensive care · 2021Article
- Characteristics of ESBL-Producing Enterobacterales Colonizing the Gastrointestinal Tract in Patients Admitted to the Oncological Hospital.Current microbiology · 2021Article
- Clinical and demographic features associated with infections with extended-spectrum beta-lactamase-producingAntimicrobial stewardship & healthcare epidemiology : ASHE · 2021Article
- Independent, external validation of clinical prediction rules for the identification of extended-spectrum β-lactamase-producing Enterobacterales, University Hospital Basel, Switzerland, January 2010 to December 2016.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020Article
- Carbapenem-Sparing Strategies for ESBL Producers: When and How.Antibiotics (Basel, Switzerland) · 2020Review
- Antimicrobial Resistance in Agri-Food Chain and Companion Animals as a Re-emerging Menace in Post-COVID Epoch: Low-and Middle-Income Countries Perspective and Mitigation Strategies.Frontiers in veterinary science · 2020Review
- Risk Factors of Extended-Spectrum Beta-Lactamases-ProducingInfection and drug resistance · 2020Review
- Risk factors for community-onset urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coliTurkish journal of medical sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited clinical information is available regarding community onset infections caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. A case-control study was performed to evaluate the epidemiology and risk factors of these types of infections. A case patient was defined as a person whose clinical sample yielded ESBL-producing E. coli. For each case patient, one control was randomly chosen from a group of outpatients from whom non-ESBL-producing E. coli had been isolated and for whom a clinical sample had been sent to the same laboratory for culturing during the following week. Of 108 cases of ESBL-producing E. coli, 56 (51.9%) were classified as health care associated (HCA). Univariate analysis showed male gender, HCA infection, severe underlying illness, and a prior receipt of antibiotics to be associated with ESBL-producing E. coli. In the multivariate analysis, HCA infection (odds ratio [OR], 3.18; 95% confidence interval [CI], 1.67 to 6.06; P < 0.001) and previous use of antibiotics (OR, 4.88; 95% CI, 2.08 to 11.48; P < 0.001) were found to be significantly associated with the ESBL group. In a multivariate analysis that included each antibiotic, previous use of fluoroquinolone (OR, 7.32; 95% CI, 1.58 to 34.01; P = 0.011) was significantly associated with ESBL-producing E. coli. Of 101 isolates in which ESBLs and their molecular relationships were studied, all isolates produced ESBLs from the CTX-M family (CTX-M-14, 40 isolates; CTX-M-15, 39 isolates; and other members of the CTX-M family, 22 isolates). In conclusion, this study confirms that ESBL-producing E. coli strains are a notable cause of community onset infections in predisposed patients. HCA infection and previous use of fluoroquinolone were significant factors associated with ESBL-producing E. coli in community onset infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.